The global epilepsy drugs market is estimated to be valued at US$ 10.31 billion in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period from 2024 to 2031.
The Importance Of The Epilepsy Drugs Market lies in addressing epilepsy, a chronic neurological disorder characterized by sudden recurrent seizures, affecting millions worldwide. Epilepsy drugs help prevent seizures or reduce their severity and frequency thereby improving the quality of life of patients suffering from epilepsy. There has been rising prevalence of epilepsy globally mainly due to the increasing geriatric population and growing incidences of head injuries and brain tumors. The global epilepsy drugs market is undergoing significant growth supported by the potential of new drug formulations and novel drug delivery mechanisms with reduced side effects and higher efficacy.
Key Takeaways
Key players operating in the epilepsy drugs market are Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc. Manufacturers are continuously engaged in R&D for innovative solutions to unmet needs in epilepsy treatment. The growing Epilepsy Drugs Market Demand for effective treatment of epilepsy is propelling market growth. Epilepsy severely impacts the quality of life of millions of people globally due to recurrent seizures. Hence, there is a pressing need for reliable, safe and targeted anti-epileptic drugs. Moreover, greater investment in R&D by key industry players aimed at developing new generation drugs is expected to contribute significantly to market expansion over the forecast period. The global epilepsy drugs market is expanding owing to increasing focus on better access to diagnosis and treatment in developing regions. Several initiatives are being undertaken by healthcare organizations and governments to spread awareness and improve epilepsy care in Asia Pacific, Latin America, Middle East and Africa. Growing healthcare expenditure and initiatives towards reducing treatment costs in low and middle income countries are stimulating market growth on a global scale.
Market Key Trends
Anti-epileptic drug delivery through novel formulations is one of the key trends influencing market revenues positively. Oral drug delivery is being replaced by alternative delivery routes such as transdermal patches, intranasal sprays and subcutaneous implants owing to better patient compliance, controlled drug release and reduced side effects. Another significant trend is the shift towards precision medicine approach involving personalized treatment regimens based on specific epilepsy types and patient comorbidities. This is expected to fuel the development of targeted AEDs for different epilepsy phenotypes and genotypes in the forthcoming years.
Porter’s Analysis
Threat of new entrants: The Epilepsy Drugs Market Size and Trends requires huge investment and time for R&D of new drugs. This acts as a barrier for new companies.
Bargaining power of buyers: The buyers have low bargaining power as the neurological disorder requires treatment and has fewer alternatives.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of substitute resources and focus of companies on in-house manufacturing.
Threat of new substitutes: Potential threat as researchers are working on developing new generation drugs and alternative therapies. Competitive rivalry: Intense competition exists between major players to sustain in the market. North America holds the major share of the epilepsy drugs market owing to growing prevalence of neurological disorders, established healthcare infrastructure and availability of advanced treatments.
Asia Pacific is poised to witness fastest growth during the forecast period due to rising healthcare spending, increasing disposable income and growing awareness.
Explore More Related Article On- Gastroesophageal Reflux Disease Treatment Devices Market
For Deeper Insights, Find the Report in the Language that You want.
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
The global Epilepsy Drugs Market is anticipated to rise at a staggering CAGR in the forthcoming period.
Epilepsy drugs have pharmacokinetic properties and are administered to children, adults, and adolescents.
Carbamazepine is applicable for focal seizures with strong properties of inducing and enables development of milder tolerance level that could be increased weekly.Epilepsy drugs market is highly driven by rise in cases of stroke, brain tumors, and brain injury.
Antiepileptic drugs are prescribed due to the rising demands for treatment for epilepsy.
Adoption of novel approach by manufacturers for production of therapeutic drugs also contributes to the market growth in the forecast period.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/epilepsy-drugs-market/request-sampleChange in lifestyle and increase in geriatric population with unmet medical needs along with rise in awareness is expected to trigger the market growth in the near future.
However, rise in demand for generic drugs and availability of cheaper substitutes are likely to hinder the market growth in the forecast period.On the basis of generation, the epilepsy drugs market is segmented as first generation epileptic drugs, second generation epileptic drugs, and pipeline drugs.
